Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes.

PURPOSE

To detect alterations in DNA damage repair (DDR) genes, measure homologous recombination deficiency (HRD), and correlate these findings with clinical outcome in patients with leiomyosarcoma (LMS).

PATIENTS AND METHODS

Patients with LMS treated at Memorial Sloan Kettering (MSK) Cancer Center who consented to prospective targeted next-generation sequencing with MSK-IMPACT were screened for oncogenic somatic variants in one of 33 DDR genes; where feasible, an experimental HRD score was calculated from IMPACT data. Progression-free survival (PFS) and overall survival (OS) were estimated after stratifying patients by DDR gene alteration status and HRD score.

RESULTS

Of 211 patients with LMS, 20% had an oncogenic DDR gene alteration. Univariable analysis of PFS in 117 patients who received standard frontline chemotherapy in the metastatic setting found that an altered homologous recombination pathway gene was significantly associated with shorter PFS (hazard ratio [HR], 1.79; 95% CI, 1.04 to 3.07; = .035). Non- homologous recombination gene alteration was associated with shorter PFS (HR, 2.61; 95% CI, 1.35 to 5.04; = .004) compared with -altered and wild-type homologous recombination genes. Univariable analysis of OS from diagnosis in the entire cohort of 211 patients found that age, tumor size, number of metastatic sites, localized disease, and non- homologous recombination gene alteration were significantly associated with OS. On multivariable analysis, non- homologous recombination pathway gene alteration remained significant (HR, 4.91; 95% CI, 2.47 to 9.76; < .001). High HRD score was not associated with a different PFS or OS.

CONCLUSION

Patients with LMS with homologous recombination pathway gene alterations have poor clinical outcomes, particularly those with non- gene alterations. HRD score calculated from a targeted exome panel did not discern disparate clinical outcomes.